Last updated: 11/07/2018 03:31:58
XP066: A Phase 1, Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of XP13512 (GSK1838262) Sustained Release (SR) Tablets in Patients with Severe Renal Impairment and End Stage Renal Disease (ESRD) Patients on Hemodialysis
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: XP066: A Phase 1, Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of XP13512 (GSK1838262) Sustained Release (SR) Tablets in Patients with Severe Renal Impairment and End Stage Renal Disease (ESRD) Patients on Hemodialysis
Trial description: XP066: A Phase 1, Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of XP13512 (GSK1838262) Sustained Release (SR) Tablets in Patients with Severe Renal Impairment and End Stage Renal Disease (ESRD) Patients on Hemodialysis
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Lal R, Sukbuntherbg J, Luo W, Chen D, Blumenthal R, Ho J, Cundy K. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil in subjects with varying degrees of renal function. Clin Ther. 2012;34(1):201-213.
Medical condition
Restless Legs Syndrome
Product
gabapentin enacarbil
Collaborators
Not applicable
Study date(s)
January 2007 to November 2007
Type
Not applicable
Phase
1
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2007-19-11
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website